144 related articles for article (PubMed ID: 17436085)
1. Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis.
Tahan V; Eren F; Avsar E; Yavuz D; Yuksel M; Emekli E; Imeryuz N; Celikel C; Uzun H; Haklar G; Tozun N
Dig Dis Sci; 2007 Dec; 52(12):3465-72. PubMed ID: 17436085
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
3. [An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis].
Zhao CY; Wang YD; Zhou JY; Jia B; Cui JF
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):450-5. PubMed ID: 17594812
[TBL] [Abstract][Full Text] [Related]
4. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.
Zhao JS; Zhu FS; Liu S; Yang CQ; Chen XM
Chin Med J (Engl); 2012 Jul; 125(13):2316-21. PubMed ID: 22882855
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs.
Sener G; Sehirli AO; Gedik N; Dülger GA
Burns; 2007 Aug; 33(5):587-93. PubMed ID: 17467912
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
[TBL] [Abstract][Full Text] [Related]
9. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Sponseller CA; Hampton K; Bacon BR
J Hepatol; 2003 Apr; 38(4):434-40. PubMed ID: 12663234
[TBL] [Abstract][Full Text] [Related]
10. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
[TBL] [Abstract][Full Text] [Related]
11. The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats.
Liu S; Wu HJ; Zhang ZQ; Chen Q; Liu B; Wu JP; Zhu L
Eur J Pharmacol; 2011 Jan; 650(1):384-9. PubMed ID: 20965162
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
Ratziu V; Charlotte F; Bernhardt C; Giral P; Halbron M; Lenaour G; Hartmann-Heurtier A; Bruckert E; Poynard T;
Hepatology; 2010 Feb; 51(2):445-53. PubMed ID: 19877169
[TBL] [Abstract][Full Text] [Related]
13. Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats.
Tahan V; Atug O; Akin H; Eren F; Tahan G; Tarcin O; Uzun H; Ozdogan O; Tarcin O; Imeryuz N; Ozguner F; Celikel C; Avsar E; Tozun N
J Pineal Res; 2009 May; 46(4):401-7. PubMed ID: 19552763
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
15. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency.
Kirsch R; Clarkson V; Verdonk RC; Marais AD; Shephard EG; Ryffel B; de la M Hall P
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):174-82. PubMed ID: 16706830
[TBL] [Abstract][Full Text] [Related]
16. Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats.
Luo ZL; Tang LJ; Wang T; Dai RW; Ren JD; Cheng L; Xiang K; Tian FZ
J Gastroenterol Hepatol; 2014 Jan; 29(1):215-22. PubMed ID: 24117897
[TBL] [Abstract][Full Text] [Related]
17. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
[TBL] [Abstract][Full Text] [Related]
18. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis.
Aghazadeh S; Amini R; Yazdanparast R; Ghaffari SH
Exp Toxicol Pathol; 2011 Sep; 63(6):569-74. PubMed ID: 20471811
[TBL] [Abstract][Full Text] [Related]
19. Modulatory role of Co-enzyme Q10 on methionine and choline deficient diet-induced non-alcoholic steatohepatitis (NASH) in albino rats.
Saleh DO; Ahmed RF; Amin MM
Appl Physiol Nutr Metab; 2017 Mar; 42(3):243-249. PubMed ID: 28177750
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
